How to manage patients with gout

References

• Richette P, Bardin T. Gout. Lancet 2010;375:318-28
   PubMed Web of Science ®Google Scholar
• Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136-41
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48(Suppl 2):ii9-14
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout, part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi GP, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension the PIUMA study. Hypertension 2000;36:1072-8
   PubMed Web of Science ®Google Scholar
• Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006;48:761-71
   PubMed Web of Science ®Google Scholar
• McCarty DJ. Gout without hyperuricemia. JAMA 1994;271:302-3
   PubMed Web of Science ®Google Scholar
• Pascual E, Doherty M. Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate. Ann Rheum Dis 2009;68:3-7
   PubMed Web of Science ®Google Scholar
• Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5
   PubMed Web of Science ®Google Scholar
• Jelley MJ, Wortmann R. Practical steps in the diagnosis and management of gout. BioDrugs 2000;14:99-107
   PubMed Web of Science ®Google Scholar
• Lawry GV 2nd, Fan PT, Bluestone R. Polyarticular versus monoarticular gout: a prospective, comparative analysis of clinical features. Medicine 1988;67:335-43
   PubMed Web of Science ®Google Scholar
• Dirken-Heukensfeldt KJ, Teunissen TA, van de Lisdonk H, et al. Clinical features of women with gout arthritis. A systematic review. Clin Rheumatol 2010;29:575-82
   PubMed Web of Science ®Google Scholar
• Rott KT, Agudelo CA. Gout. JAMA 2003;289:2857-60
   PubMed Web of Science ®Google Scholar
• Beutler A, Schumacher HR Jr. Gout and ‘pseudo-gout’: when are arthritic symptoms caused by crystal disposition? Postgrad Med 1994;95:103-6
   PubMed Web of Science ®Google Scholar
• Dore RK. The gout diagnosis. Cleve Clin J Med 2008;75:S17-21
   PubMedGoogle Scholar
• Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care 2005;11:S443-50
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15
   PubMed Web of Science ®Google Scholar
• Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ 2012;344:d8190
   PubMed Web of Science ®Google Scholar
• Hamburger M, Baraf HS, Adamson TC, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed 2011;39:98-123
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46
   PubMed Web of Science ®Google Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012b American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64:1447-61
   PubMed Web of Science ®Google Scholar
• Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60
   PubMed Web of Science ®Google Scholar
• Hunt JM, McTigue JC, Edwards NL. Diagnosis and management of gout in 2011. J Musculoskel Med 2011;28. Avalilable at: http://www.musculoskeletalnetwork.com/gout/content/article/1145622/1973052. Last accessed: 8th April 2013.
   Google Scholar
• Garcia-Valladares I, Khan T, Espinoza LR. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskel Dis 2011;3:245-53
   Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the COMFIRMS trial. Arthritis Res Ther 2010;12:R63
   PubMed Web of Science ®Google Scholar
• Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii15-19
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European Public Assessment Report – Adenuric. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000777/WC500021813.pdf Last accessed April 8th 2013
   Google Scholar
• Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm 2011;68:389-98
   PubMed Web of Science ®Google Scholar
• Reinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase. Therapeut Clin Risk Manag 2010;6:543-50
   PubMed Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28
   PubMed Web of Science ®Google Scholar
• So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76
   PubMed Web of Science ®Google Scholar
• Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging 1998;13:229-43
   PubMed Web of Science ®Google Scholar
• Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63
   PubMed Web of Science ®Google Scholar
• Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging 2011;28:591-603
   PubMed Web of Science ®Google Scholar
• Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr 2012;12:11
   PubMed Web of Science ®Google Scholar
• Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 2008;20:198-202
   PubMed Web of Science ®Google Scholar
• Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis 2007;66:1269-70
   PubMed Web of Science ®Google Scholar
• Roddy E. Hyperuricemia, gout, and lifestyle factors. J Rheumatol 2008;35:1689-91
   PubMed Web of Science ®Google Scholar
• Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012;71:1490-5
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the management of gout. Rheumatology 2007;46:1372-4
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Primatesta P, Ferreira A, et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011;50:973-81
   PubMed Web of Science ®Google Scholar
• Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Dalbeth N, Lindsay K. The patient’s experience of gout: new insights to optimize management. Curr Rheumatol Rep 2012;14:173-8
   PubMedGoogle Scholar
• Ogdie AR, Hoch S, Dunham J, et al. A roadmap for education to improve the quality of care in gout. Curr Opin Rheumatol 2010;22:173-80
   PubMed Web of Science ®Google Scholar